Publications - Original Research

Narra HP, Shubitz LF, Mandel MA, Trinh HT, Griffin KJ, Buntzman AS, Frelinger JA, Galgiani JN, Orbach MG. “A Coccidioides CPS1 deletion mutant is avirulent and protects mice from lethal infection.” Infect. Immun. Accepted manuscript posted online 1 August 2016, doi:10.1128/IAI.00633-16

Rigby MR, Harris K, Pinckney A, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi DM, Raskin P, Keyes-Elstein L, Long S, Kanaparthi S, Lim N, Phippard D, Soppe C, Fitzgibbon M, McNamara J, Nepom GT, Ehlers MR. “Durable efficacy of alefacept in new-onset Type 1 diabetes: Evidence for lasting modulation of effector and regulatory T cells.” 2014 (Aug) J. Clin.
Invest. 125(8):3285-96. doi: 10.1172/JCI81722. Published on line 20 July 2015

Towne JW, Wagner AM, Griffin KJ, Buntzman AS, Frelinger JA, Besselsen DG. “Elimination of Pasteurella pneumotropica from a mouse barrier facility by using a modified enrofloxacin treatment
regimen.” J Am Assoc Lab Anim Sci. 2014 53(5):517-22. PMID: 25255075; PMC4181694.

Levin SM, Baker EH, Zein WM, Zhang Z, Quezado ZMN, Miao N, Gropman A, Griffin KJ, Bianconi S, ChandraG, Khan OI, Caruso RC, Mukherjee AB. “A Bench-to-Bedside Clinical Trial Using a Combination of Cystagon and Mucomyst for Patients with Infantile Neuronal Ceroid Lipofuscinosis.” Lancet Neurol. 2014 (Aug) 13(8):777-87. doi: 10.1016/S1474-4422(14)70142-5. Published on line 3 July 2014

Griffin KJ, Thompson P, Gottschalk M, Kyllo JH, Rabinovitch A. “Combination Therapy With Sitagliptin and Lansoprazole to Restore Pancreatic Beta Cell Function in Recent-Onset Type 1 Diabetes (REPAIR-T1D): 12 month results of a Multi-center Randomized, Placebo-controlled Phase 2 Trial.” Lancet Diabetes Endocrinol. 2014 (Sep) 2(9):710-8. doi: 10.1016/S2213- 8587(14)70115-9. Published on line 3 July 2014.

Rigby MR, DiMeglio LA, Rendell MS, Felner EI, dostou JM, Gitelman SE, Patel CM, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi DM, Raskin P, Moran A, Russell WE, Pinckney A, Keyes-Elstein L, Howell M, Aggarwal S, Lim N, Phippard D, Nepom GT, McNamara J, Ehlers MR. “Targeting effector memory T cells with alefacept in new onset type 1 diabetes (T1DAL Study): 12 month results of a randomised, double-bind, placebo-controlled phase 2 trial.”  Lancet Diab. Endocrinol. 2013 1(4):284-94.   http://dx.doi.org/10.1016/S2213-8587(13)70111-6
 
Almeida MQ, Muchow M, Boikos M, Bauer AJ, Griffin KJ, Tsang KM, Cheadle C, Watkins T, Wen F, Starost M, Bossis I, Nesterova M, Stratakis CA. “Prkar1a haploinsufficiency in mice leads to an overall increase in tumors caused by other genetic defects or chemicals..” Hum Mol Genet. 2010 19(8):1387-98. PMCID: PMC2846157.
 
Louiset E, Stratakis CA, Perraudin V, Griffin KJ, Libé R, Cabrol S, Fève B, Young J, Groussin L, Bertherat J, and Lefebvre H. “The paradoxical increase in cortisol secretion induced by dexamethasone in primary pigmented nodular adrenocortical disease involves a glucocorticoid receptor-mediated effect of dexamethasone on protein kinase A catalytic subunits.” J Clin Endocrinol Metab. Jul;94(7):2406-13. Epub Apr 21. 2009. PMCID: PMC2708955
 
Horvath A, Giatzakis C, Robinson-White A, Boikos S, Griffin KJ, Stein E, Kamvissi V, Soni P, Bossis I, de Herder W, Carney JS, Bertherat J, Gregersen PK, Remmers EF, Stratakis CA. “Adrenal hyperplasia and adenomas are associated with inhibition of phosphodiesterase 11A in carriers of PDE11A sequence variants that are frequent in the population” Cancer Res. 2006 Dec 15;66(24):11571-5.
 
Boikos S, Giatzakis C, Robinson-White A, Groussin L, Griffin KJ, Stein E, Levine E, Delimpasi G, Hsiao HP, Keil M, Heyerdahl S, Matyakhina L, Libe R, Fratticci A,Horvath A Kirschner LS, Cramer K, Gaillard RC, Bertagna X, Carney JA, Bertherat J, Bossis I, Stratakis CA. A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasia. Nat. Genet. 2006 Jul;38(7):794-800.
 
Batista D, Courkoutsakis NA, Oldfield EH, Griffin KJ, Keil M, Patronas NJ, Stratakis CA. “Detection of ACTH-secreting pituitary adenomas by magnetic resonance imaging (MRI) in children and adolescents with Cushing disease.” J Clin Endocrinol Metab. 90(9): 5134-40, 2005.
 
Griffin KJ, Kirschner LS, Matyakhina L, Stergiopoulos SG, Robinson-White A, Lenherr S, Weinberg FD, Claflin ES, Batista D, Bourdeau I, Voutetakis A, Sandrini F, Meoli E, Bauer AJ, Cho-Chung YS, Bornstein SR, Carney JA, Stratakis CA. “A transgenic mouse bearing an antisense construct of regulatory subunit type 1A of protein kinase A develops endocrine and other tumors: comparison to Carney complex and other PRKAR1A-induced lesions.”  J. Med. Genet 41: 923-931, 2004
 
Griffin KJ, Kirschner LS, MatyakhinaL, Stergiopoulos SG, Robinson-WhiteA, Lenherr S, Weinberg F, ClaflinES, Meoli EM, Cho-ChungYS, Stratakis CA. “Down-regulation of regulatory subunit type 1A of protein kinase A leads to endocrine and other tumors.” Cancer Res. 64:8811-5, 2004.
 
Courcoutsakis NA, Patronas NJ, Cassarino D, Griffin KJ, Keil M, Ross JL, Carney JA, Stratakis CA. “Hypodense nodularity on computed tomography: novel imaging and pathology of micronodular adrenocortical hyperplasia associated with myelolipomatous change.” J. Clin Endocrinol. Metab. 89(8):3737-8, 2004.
 
Bossis I, Voutetakis A, Matyakhina L, Pack S, Abu-Asab M, Bourdeau I, Griffin KJ, Courcoutsakis N, Stergiopoulos S, Batista D, Tsokos M, Stratakis CA. “A pleiomorphic GH pituitary adenoma from a Carney complex patient displays universal allelic loss at the protein kinase A regulatory subunit 1A (PRKARIA) locus.” J. Med. Genet. 41(8):596-600, 2004.
 
Gunther DF, Bourdeau I, Matyakhina L, Cassarino D, Kleiner DE, Griffin KJ, Courkoutsakis N, Abu-Asab M, Tsokos M, Keil M, Carney JA, and Stratakis CA. “Cyclical Cushing syndrome presenting in infancy: an early form of primary pigmented nodular adrenocortical disease, or a new entity?” J. Clin. Endocrinol. Metab. 89(7):3173-82, 2004.
 
Griffin KJ, Degala, GD, Eisenreich W, Müller F, Bacher A, and Frerman FE. “31P-NMR spectroscopy of human and Paracoccus denitrificans electron transfer flavoprotein in the oxidized and reduced states.” Eur. J. Biochem. 255(1):125-32, 1998.
 
Griffin KJ, Dwyer TM, Manning MC, Meyer JD, Carpenter JF, and Frerman FE.   “Alpha-T244M mutation affects the redox, kinetic, and in vitro folding properties of Paracoccus denitrificans electron transfer flavoprotein.” Biochemistry 36(14):4194-4202, 1997.
 
Griffin KJ. “Mutagenesis and Characterization of Electron Transfer Flavoprotein from Paracoccus denitrificans.” Cell and Developmental Biology Program, University of Colorado Health Sciences Center, 1996.
 
Bedzyck, L.A., Escuderdo KW, Gill RE, Griffin KJ, and Frerman FE. “Cloning, sequencing, and expression of the genes encoding subunits of Paracoccus denitrificans electron transfer flavoprotein.” J. Biol. Chem.  268(27): 20211 - 20217, 1993.
 
Griffin KJ, Gierse J, Krivi G, and Fitzpatrick FA. “Opioid peptides are substrates for the bifunctional enzyme LTA4 hydrolase/aminopeptidase.” Prostaglandins 44:251 - 57, 1992.
 
Griffin KJ, Hong T, and Levy JV. “The benzodiazepine receptor ligands RO 5-4864 and RO 15-1788 do not block the inhibition of PAF-induced platelet aggregation seen with the hetrazepine WEB 2086.”  Biochem. & Biophys. Res. Comm. 160 (1): 263-7, 1989.
 
Griffin KJ, and Levy JV. “The Thieno-triazolodiazepine WEB 2086 inhibits platelet aggregation and ATP release from porcine platelets induced by platelet activating factor (PAF).” Thrombosis Res. 51: 219 - 223, 1988.